Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Novo Nordisk A/S - June 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Novo Nordisk A/S - March 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Novo Nordisk A/S: Update following rating affirmation at A1, outlook c...

Our credit view of Novo Nordisk reflects its leading position in diabetes and obesity care, and very strong credit metrics, against limited therapeutic and product diversification.

Novo Nordisk A/S - December 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Novo Nordisk A/S: Update following rating affirmation

Our credit view of this issuer reflects its good track record in successfully developing and commercialising new treatments within diabetes care, offset by A degree of M&A risk.

Novo Nordisk A/S - September 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Novo Nordisk A/S - June 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Novo Nordisk A/S - March 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Novo Nordisk A/S: Update to credit analysis

Our credit view of Novo Nordisk reflects its leading position in diabetes and obesity care, and strong credit metrics, against limited therapeutic diversification and a degree of M&A risk.

Bryan, Garnier & Co Healthcare Daily

Coverage update

To reprioritize resources, we are dropping coverage of AstraZeneca, bioMerieux, GSK, Novartis, Novo Nordisk, Roche, Sanofi, Lysogene and Quantum Genomics.

Novo Nordisk A/S - December 2022 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Vermilion Compass: Weekly Equity Strategy

Many Indexes and Sectors Testing Resistance Note: This Compass is an abbreviated report. We will resume our normal report layout next week. In our previous Compass (Jan. 24), we discussed our belief that equities were still in the midst of a rally/short squeeze, but that the rally is likely to fizzle in the 4100-4165 area (the top-end of our expected 2023 trading range) on the S&P 500. And, as you will see below, countless other indexes and Sectors are testing important resistance levels. We c...

Novo Nordisk A/S - September 2022 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Vermilion Compass: Weekly Equity Strategy

Indexes Form Bear Flag Patterns Within Downtrends We continue to view the price action over the past month as a bear market bounce in the S&P 500, Nasdaq 100 (QQQ), and Russell 2000 (IWM), as each index appears to be forming a bearish flag pattern. Until the S&P 500, QQQ, and IWM can break above their YTD downtrends, we remain bearish, and believe investors should be using rallies to reduce overall exposure in preparation for new lows ahead... see charts below. U.S. Dollar, 10-Yr Treasury Yiel...

Novo Nordisk A/S - March 2022 (LTM): Peer Snapshot

Compares key performance metrics against industry peers

Novo Nordisk A/S: Update to credit analysis

Our credit view of Novo Nordisk reflects its leading position in diabetes care and strong credit metrics, against limited therapeutic diversification and a degree of M&A risk.

Vermilion Compass: Weekly Equity Strategy

10-Year Treasury Yield Testing 40-Year Resistance; Upgrading Health Care to Overweight Whether or not the lows for this correction have already been established remains to be seen, but evidence is mounting that suggests a test of the lows, and possibly a break to new lows, is increasingly likely. Regardless, continue to stick with the commodity and defensive Sectors, all of which hit new price and RS highs in recent days. 10-Year Treasury Yield. We have discussed our expectations for rising ra...

Novo Nordisk A/S - December 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers